Stock AnalizLakefront Biotherapeutics NV LKFT
Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026
Lakefront Biotherapeutics NV (LKFT) is a healthcare company listed in the US with a market value of about $2.2B. In the twelve months to September 30, 2026 it had revenue of $1.0B and net income of $877M, a net margin of 85.9%.
Its overall Stock Analiz score is 2.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is track record (1/5).
Key numbers: a P/E of 2.6, 5-year revenue growth of 15% a year, a 5-year average ROIC of -2%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 80% below the current price.
Score: 2.0 / 5
Checks passed
- P/E below 25
- P/E below the industry median
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
Checks not passed
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Profit margin improving
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
- Profitable 5 years in a row
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.0B | $1.3B | $286M | $265M | $257M | $265M | $651M | $995M | $352M | $187M | $160M |
| Net income | $877M | $377M | $77M | $234M | -$233M | -$117M | -$375M | $168M | -$34M | -$139M | $57M |
| Free cash flow | -$222M | -$319M | -$350M | -$469M | -$563M | -$632M | -$577M | $3.6B | -$175M | -$183M | $248M |
| EPS (diluted) | $13.25 | $5.72 | $1.17 | $3.55 | $-3.53 | $-1.77 | $-5.69 | $2.55 | $-0.51 | $-2.11 | $0.86 |
| Net margin | 85.9% | 28.8% | 26.9% | 88.3% | -90.4% | -44.0% | -57.6% | 16.9% | -9.5% | -74.2% | 35.6% |
| ROIC | — | 7.2% | -5.1% | -2.5% | -4.1% | -5.1% | -5.3% | 10.1% | -3.1% | -7.0% | -1.5% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
What is Lakefront Biotherapeutics NV’s P/E ratio?
About 2.6, based on the last twelve months of diluted earnings per share.
Is Lakefront Biotherapeutics NV stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 80% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Lakefront Biotherapeutics NV pay a dividend?
Not currently.
Is Lakefront Biotherapeutics NV a good stock to buy?
We do not give buy or sell advice. Lakefront Biotherapeutics NV scores 2.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.